Breast Cancer Research and Treatment最新文献

{"title":"Comment on \"Effects of a sensorimotor-based, movement quality-focused intervention on functional mobility in breast cancer survivors: a multicenter randomized controlled trial\".","authors":"Kunyu Han, Changguo Zhao","doi":"10.1007/s10549-026-08058-5","DOIUrl":"10.1007/s10549-026-08058-5","url":null,"abstract":"<p><p>This correspondence comments on the multicenter randomized trial of the Rehabilitation through Movement and Perception (ReMAP) program in breast cancer survivors. Although the study highlights the potential value of sensorimotor-focused rehabilitation, clarification is needed regarding participant accounting, the intention-to-treat analysis, the clinical interpretation of the Timed Up and Go outcome, control-group exposure, and the proposed mechanism linking movement quality to functional mobility.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with discordance between pathological and radiological tumor size and risk of re-excision in breast-conserving surgery: a post-hoc analysis within a randomized trial.","authors":"Christos Kollatos, Eirini Pantiora, Allan Jazrawi, Fredrik Wärnberg, Staffan Eriksson, Andreas Karakatsanis","doi":"10.1007/s10549-026-08052-x","DOIUrl":"10.1007/s10549-026-08052-x","url":null,"abstract":"<p><strong>Purpose: </strong>Accurate preoperative radiological assessment is essential in breast-conserving surgery (BCS) to achieve clear margins while minimizing unnecessary healthy tissue excision. Discrepancies between radiological and pathological tumor size may contribute to re-excision. This study evaluated factors associated with radiology-pathology discordance and their impact on re-excision.</p><p><strong>Methods: </strong>This post hoc analysis of the MagTotal randomized trial included patients with non-palpable breast cancer undergoing BCS with lesion localization and sentinel lymph node dissection. The Pathology-to-Radiology Ratio (PRR) quantified discordance between size on preoperative imaging and specimen pathology. Primary outcomes were predictors of PRR and re-excision. A multivariable model was used to construct a nomogram for predicting PRR.</p><p><strong>Results: </strong>Among 414 patients (median age 65 years; median tumor size 10.3 mm), MRI was performed in 24.4%. Median PRR was 1.25, suggesting systematic underestimation. MRI consistently overestimated tumor size in most subtypes but provided more accurate estimates for invasive lobular carcinoma (ILC), compared with conventional imaging. Independent predictors of discordance included ILC, high grade, and small tumor size. Eleven patients (2.7%) required re-excision, which was associated with tumor biology and mismatches between imaging and pathology but not with MRI use.</p><p><strong>Conclusion: </strong>Re-excision in non-palpable breast cancer is primarily driven by tumor biology and radiology-pathology mismatch. Although MRI improved size assessment in ILC, it did not reduce re-excision rates. Integrating imaging with biological factors, supported by predictive tools such as a nomogram, may refine surgical planning in BCS.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging.","authors":"T W W Yang, A K Rose, J Matheson, K Elder, C MacCallum, C Nickson, G B Mann","doi":"10.1007/s10549-026-08049-6","DOIUrl":"10.1007/s10549-026-08049-6","url":null,"abstract":"<p><strong>Purpose: </strong>The role of contrast-based imaging (CBI) at diagnosis in early breast cancer remains debated. More sensitive baseline staging may identify synchronous disease that would otherwise present as early ipsilateral or contralateral events. We examined whether CBI at diagnosis is associated with differences in early locoregional outcomes.</p><p><strong>Methods: </strong>A retrospective cohort study of women with early invasive breast cancer or ductal carcinoma in situ (DCIS). Patients were grouped according to whether they underwent CBI (CEM or MRI) at diagnosis. All underwent mammographic surveillance including contrast-enhanced mammography (CEM). Locoregional events from diagnosis to 30 June 2025 were identified and evaluated. Cox proportional hazards models to assess associations between CBI use and subsequent locoregional events were adjusted for age, calendar period, mammographic density (MD), and stage.</p><p><strong>Results: </strong>Among 1,106 women (594 CBI, 512 non-CBI) diagnosed between April 2015 and June 2022, there were 60 locoregional events (39 invasive, 21 DCIS). Patients who underwent CBI had fewer subsequent locoregional events. After adjustment, CBI use at diagnosis was associated with significantly lower 5-year event rates among women with invasive cancer (adjusted HR 0.50, 95% CI 0.26-0.98, p = 0.043), particularly those with Luminal A/B phenotypes, low MD, and with fewer contralateral events in invasive index cases (adjusted HR 0.19, 95% CI 0.05-0.71, p = 0.014). Features of subsequent events (including tumour grade, behaviour, and invasive size) were not found to differ between groups.</p><p><strong>Conclusion: </strong>Inclusion of CBI in local staging of early breast cancer was associated with lower rates of locoregional events over five years. These findings support broader consideration of CBI use for local staging at diagnosis.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148720610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of a novel prognostic staging system for breast cancer incorporating age at diagnosis.","authors":"Helen M Johnson, Wenli Dong, Yu Shen, William Irish, Jan H Wong, Nasreen A Vohra, Nina Tamirisa","doi":"10.1007/s10549-026-08055-8","DOIUrl":"10.1007/s10549-026-08055-8","url":null,"abstract":"<p><strong>Purpose: </strong>Age at diagnosis is an independent prognostic variable for breast cancer-specific and overall survival (OS). We previously developed a novel prognostic staging system that incorporates age and demonstrated refined risk stratification compared with the current American Joint Committee on Cancer (AJCC) staging schema. We now aim to externally validate this staging system.</p><p><strong>Methods: </strong>The National Cancer Database was used to identify adult females diagnosed with invasive breast cancer from 2010-2015. Women with prior malignancy, unknown vital status, or unknown AJCC clinical prognostic stage (CPS) variables were excluded. Serial multivariable Cox's proportional hazards models evaluated associations between OS and CPS +/- age +/- effect modification (CPS by age interaction). Models were evaluated using concordance index (C-index).</p><p><strong>Results: </strong>Among 663,659 patients, the median age was 60 years (IQR 51-70) and the median follow-up was 91.3 months. At last follow-up, 133,273 patients (20.1%) were dead. The model that incorporated both age and effect modification had the highest C-index (0.7852, versus 0.6881 for the model excluding age and 0.7847 for the model without effect modification), indicative of the best predictive performance. Using this model to predict OS stratified by CPS showed differential survival across the age spectrum, consistent with the initial model. Within each stage group, women diagnosed at age 40 had the best survival, whereas women at the extremes of age had inferior survival.</p><p><strong>Conclusion: </strong>This analysis provides external validation of our novel prognostic staging system for breast cancer. Future editions of AJCC may consider incorporating age to achieve more accurate survival predictions.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials.","authors":"Uri Bender, Karine Ronan, Amal Aljuhani, Jacqueline Savill, Eitan Amir","doi":"10.1007/s10549-026-08056-7","DOIUrl":"10.1007/s10549-026-08056-7","url":null,"abstract":"<p><strong>Purpose: </strong>Adjuvant cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve outcomes in hormone receptor-positive (HR+), HER2-negative early breast cancer, though trial results have been heterogeneous. Menopausal status and endocrine therapy backbone may contribute to variability in treatment effect. We performed a meta-analysis evaluating whether menopausal status influences the efficacy of adjuvant CDK 4/6 inhibition.</p><p><strong>Methods: </strong>A systematic review of phase III randomized trials evaluating adjuvant CDK4/6i in HR+/HER2- early-stage breast cancer was conducted. Trial-level hazard ratios (HRs) and 95% confidence intervals (CIs) for iDFS and OS were extracted separately for pre-/peri-menopausal and postmenopausal subgroups. HRs were pooled using random-effects modelling (DerSimonian-Laird method) with inverse-variance modeling. Heterogeneity was assessed using I² statistics. A sensitivity analysis limited to approved CDK4/6i (ribociclib and abemaciclib) was performed.</p><p><strong>Results: </strong>Four trials comprising 17,748 participants were included, of whom 45% were pre-/peri-menopausal and 55% were postmenopausal. Pooled iDFS HRs were 0.80 (95% CI 0.67-0.97, I²=64%) in pre-/peri-menopausal patients and 0.79 (95% CI 0.72-0.86, I²=0%) in postmenopausal patients. Pooled OS HRs were 1.02 (95% CI 0.67-1.54, I²=80%) in pre-/peri-menopausal and 0.89 (95% CI 0.78-1.03, I²=0%) in postmenopausal patients. No significant subgroup differences were observed for iDFS or OS. Compared to post-menopausal participants, those who were premenopausal had 3.0% fewer absolute iDFS events at 5-6 years. Sensitivity analyses yielded consistent findings.</p><p><strong>Conclusions: </strong>Efficacy of adjuvant CDK4/6 inhibition in HR+/HER2-negative early breast cancer does not appear to be influenced by menopausal status as defined in individual trials. Greater heterogeneity among pre-/peri-menopausal patients may reflect differences in endocrine therapy backbone, tumor characteristics and patient risk.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States.","authors":"Filipa Lynce, Meng Ru, Linlin Luo, Miguel Miranda, Xiaoqing Xu, Claudine Isaacs","doi":"10.1007/s10549-026-08011-6","DOIUrl":"10.1007/s10549-026-08011-6","url":null,"abstract":"<p><strong>Purpose: </strong>Clinical benefit from adjuvant capecitabine in patients with early-stage triple-negative breast cancer (eTNBC) and deleterious BRCA1/BRCA2 mutation (BRCAm) is not well characterized. This retrospective, observational study explored the real-world effectiveness of adjuvant capecitabine in patients with eTNBC by BRCAm status.</p><p><strong>Methods: </strong>Data from adults diagnosed with eTNBC from 2016 to 2024 were captured from electronic health records in the US Flatiron Health database. Patients who initiated adjuvant capecitabine within 6 months after primary surgery and had documented BRCA status (by germline/tumor testing) were included.</p><p><strong>Results: </strong>Of 882 patients who received adjuvant capecitabine, 53 (6%) had BRCAm, and 829 (94%) had non-BRCAm tumors. Median age at eTNBC diagnosis was lower in patients with BRCAm versus non-BRCAm (47 vs. 55 years). Most patients received capecitabine after neoadjuvant treatment (BRCAm: n = 49/53, 92%; non-BRCAm: n = 755/829, 91%), and most received adjuvant capecitabine monotherapy (BRCAm: n = 52/53, 98%; non-BRCAm: n = 790/829, 95%). Survival rates from surgery to 36 months were numerically lower in patients with BRCAm versus non-BRCAm (invasive disease-free survival: 59% vs. 72%; distant disease-free survival: 59% vs. 73%; overall survival: 67% vs. 80%); these differences were maintained in sensitivity analyses of patients with profiles aligned with the CREATE-X clinical trial criteria.</p><p><strong>Conclusion: </strong>This analysis showed a trend for worse real-world survival in patients with BRCAm versus non-BRCAm eTNBC who received adjuvant capecitabine. Although descriptive, these findings suggest an unmet need for patients with BRCAm eTNBC despite adjuvant capecitabine treatment; this could be addressed through wider BRCA testing and subsequent targeted therapy for patients with BRCAm.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13468742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast skin ulceration in de novo metastatic breast cancer: incidence, predictors, and patterns of occurrence.","authors":"Celian Guyon, Fabien Guffroy, Jonathan Sabah, Louna Mossino Diaz, Luc Cabel, Jean-Yves Pierga, Toulsie Ramtohul, Pierre Loap, Claire Bonneau, Helene Didelot, Enora Laas, Thomas Gaillard","doi":"10.1007/s10549-026-08035-y","DOIUrl":"10.1007/s10549-026-08035-y","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to identify factors associated with breast skin ulceration (BSU) and to describe its timing and patterns of occurrence in de novo metastatic breast cancer (MBC).</p><p><strong>Methods: </strong>We conducted a retrospective cohort study including women diagnosed with de novo MBC between 2008 and 2019 at Institut Curie. Clinical, pathological, and treatment-related data were extracted from the ESME database, a large, nationwide French real-world database dedicated to metastatic breast cancer. The primary endpoint was the presence or development of BSU. Secondary endpoints included progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>Among 669 patients with de novo MBC, 53 (7.9%) presented with or developed BSU. Ulceration was present at diagnosis in 50 cases (94%), whereas secondary BSU during follow-up was rare (n = 3). All secondary BSU occurred in non-operated inflammatory tumors (T4d), and no secondary BSU was observed in non-inflammatory disease. Larger tumor size, inflammatory presentation, and higher metastatic burden were associated with BSU. In unadjusted analyses, BSU was associated with shorter PFS and OS, but this association was no longer significant after multivariable adjustment.</p><p><strong>Conclusions: </strong>Breast skin ulceration in de novo MBC is an uncommon event that primarily reflects aggressive inflammatory tumor behavior rather than inadequate locoregional management. Secondary BSU is exceptionally rare and confined to inflammatory tumors. Systematic routine surgical intervention solely to prevent ulceration appears unjustified in non-inflammatory disease.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction.","authors":"Tyler P Shern, Victoria Chamberlain, Logan R Holt, Michele A Gadd, Francys C Verdial, Tolga Ozmen, Michelle C Specht, Charles S Dai, Barbara L Smith","doi":"10.1007/s10549-026-08054-9","DOIUrl":"10.1007/s10549-026-08054-9","url":null,"abstract":"<p><strong>Purpose: </strong>Programmed cell death protein-1 (PD-1) inhibitors have transformed cancer therapy, but evidence suggests PD-1 signaling modulates µ-opioid receptor activity, potentially attenuating opioid analgesia. This study evaluated the effect of PD-1-based neoadjuvant chemotherapy (NAC) on perioperative opioid use and pain outcomes following mastectomy with immediate reconstruction.</p><p><strong>Methods: </strong>We retrospectively reviewed consecutive mastectomies with immediate reconstruction following NAC between 2020 and 2024. Patients were grouped by PD-1-based NAC (NAC + PD-1) versus NAC without PD-1 inhibitors (NAC). Patient and procedural characteristics, perioperative opioid use, pain scores, and post-discharge opioid refills were analyzed. Multivariable analysis identified predictors of post-anesthesia care unit (PACU) opioid use per hour, postoperative pain, and post-discharge refills.</p><p><strong>Results: </strong>Among 277 patients, 54 received NAC + PD-1 and 223 received NAC. BRCA1/2 mutations (38.9% vs. 7.2%, p < 0.001), bilateral surgery (92.6% vs. 67.7%, p < 0.001), and sentinel lymph node biopsy (87.0% vs. 64.6%, p = 0.001) were more common in the NAC + PD-1 group. Despite comparable preoperative analgesia and intraoperative opioids, NAC + PD-1 patients had higher PACU opioid use per hour (3.5 vs. 2.1 OMEs/hour, p = 0.029), higher maximum PACU pain scores (6.3 vs. 5.4 p = 0.011), and post-discharge opioid refills (38.9% vs. 17.0%, p = 0.001). On multivariable analysis, NAC + PD-1 (β = 1.189, p = 0.044), breast volume > 700 cm³ (β = 1.065, p = 0.029) and preoperative analgesia medications (β=-0.541, p = 0.034) predicted PACU opioid use per hour, while NAC + PD-1 (OR = 3.574, p < 0.001) and axillary lymph node dissection (OR = 1.935, p = 0.048) predicted opioid refill likelihood.</p><p><strong>Conclusion: </strong>Neoadjuvant PD-1 inhibitors were associated with increased perioperative opioid requirements. Clinicians should consider potential PD-1-related alterations in analgesic response when managing pain in this population.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148720513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging role of artificial intelligence in preoperative prediction of surgical margin status in breast cancer surgery.","authors":"Mahtab Khajeh, Mohammad Amin Shahram","doi":"10.1007/s10549-026-08053-w","DOIUrl":"10.1007/s10549-026-08053-w","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.","authors":"Jingjing Liu, Lei Liu, Ernesto Yagüe, Qianxi Yang, Teng Pan, Hui Zhao, Yunhui Hu, Jin Zhang","doi":"10.1007/s10549-026-08057-6","DOIUrl":"10.1007/s10549-026-08057-6","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"218 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}